Aspiriant LLC Takes $236,000 Position in Astrazeneca Plc $AZN

Aspiriant LLC purchased a new position in Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,567 shares of the company’s stock, valued at approximately $236,000.

Other institutional investors have also added to or reduced their stakes in the company. Binnacle Investments Inc grew its position in shares of Astrazeneca by 21.8% in the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after buying an additional 118 shares during the period. Chapin Davis Inc. boosted its stake in Astrazeneca by 3.3% during the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after acquiring an additional 120 shares in the last quarter. 44 Wealth Management LLC grew its holdings in Astrazeneca by 0.7% in the third quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock worth $1,283,000 after purchasing an additional 124 shares during the period. CoreCap Advisors LLC grew its holdings in Astrazeneca by 30.6% in the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after purchasing an additional 125 shares during the period. Finally, Highline Wealth Partners LLC increased its stake in shares of Astrazeneca by 32.0% during the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after purchasing an additional 129 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Trading Down 0.1%

NYSE AZN opened at $203.32 on Monday. Astrazeneca Plc has a one year low of $122.48 and a one year high of $212.71. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $315.33 billion, a P/E ratio of 31.04, a price-to-earnings-growth ratio of 1.53 and a beta of 0.35.

Astrazeneca Dividend Announcement

The business also recently disclosed a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were given a dividend of $1.595 per share. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio is 66.26%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Citigroup began coverage on Astrazeneca in a research report on Tuesday, January 27th. They issued a “buy” rating on the stock. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday. HSBC reiterated a “buy” rating and set a $108.00 price objective on shares of Astrazeneca in a research note on Wednesday, December 10th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Finally, Weiss Ratings started coverage on Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.